Solasia Pharma K.K

Research Solasia Pharma K.K (9SO) on Bullrun: market cap EUR 28.67M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• Ticker9SO
• ExchangeF
• CountryJapan
• SectorHealthcare
• IndustryDrug Manufacturers - Specialty & Generic
• CurrencyEUR
• Market capEUR 28.67M
• Financial periodFY2025
• RevenueEUR 429.00M
• Revenue growth35.8%
• Net income-EUR 876.00M
• Gross margin48.3%

Valuation Snapshot

latest market cap is EUR 28.67M.

About Solasia Pharma K.K

Solasia Pharma K.K. develops, markets, imports, and exports pharmaceutical products and medical devices in Japan, China, South Korea, and internationally. The company offers Episil (SP-03), an oral liquid for oral mucositis/stomatitis; DARVIAS (SP-02), an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma; and Sancuso (SP-01) for chemotherapy-induced nausea and vomiting. It also develops SP-04, which is in a preclinical trial for chemotherapy-induced peripheral neuropathy;

Frequently asked questions

What is Solasia Pharma K.K's market cap?

Solasia Pharma K.K's market capitalization is EUR 28.67M.

What does Solasia Pharma K.K do?

Solasia Pharma K.K. develops, markets, imports, and exports pharmaceutical products and medical devices in Japan, China, South Korea, and internationally. The company offers Episil (SP-03), an oral liquid for oral mucositis/stomatitis;